Best Detroit Grants for Nonprofits in Michigan

The National Institute of Allergy and Infectious Diseases (NIAID) aims to enhance the development of diagnostic tests for infectious diseases through strategic partnerships between academia and industry. By fostering collaborations, NIAID seeks to overcome barriers to commercialization, ensuring promising diagnostics reach the market effectively. This initiative aligns with NIH's mission to advance innovative technologies that improve treatment and prevention strategies for infectious diseases, ultimately contributing to public health advancements.

About

Originally conceived by Dr Bruce Mesara in 1990 as a means to carry on his philanthropic efforts beyond his lifetime, the Mesara Family Foundation was re-envisioned by his two children Amy and Douglas in 2014, and received their 501(c)(3) status from the IRS in 2015. Amy and Douglas sought out the assistance of their cousins to build upon the charitable principals on their parents, aunts and uncles.

The foundation is headquartered in Kalamazoo Michigan.

Mission

The mission of the Mesara Family Foundation is to honor the philanthropic principles of the Mesara and Pauch families by supporting carefully selected organizations that share similar values. Our focus is to provide support toward education, conservation and other causes of special family interest where our funding will make a genuine difference.

The BJA FY 2026 John R. Justice Formula Grant Program offers loan repayment assistance to local and state prosecutors and public defenders who commit to three years of service. Administered by state agencies, this program aims to alleviate the financial burden on legal professionals dedicated to public service. Applications are due by November 10, 2026, providing a crucial opportunity for eligible beneficiaries to secure support for their educational loans.

The National Oceanic and Atmospheric Administration (NOAA) is inviting proposals for projects that enhance coastal flood protection through public-private partnerships, innovative insurance products, and improved sediment management. This initiative aims to utilize natural infrastructure to bolster flood preparedness and resilience. Funding of up to $2,000,000 is available for selected projects, supporting research teams that collaborate with regional stakeholders. Proposals must be submitted via Grants.gov, ensuring accessibility to critical resources and information.

The BJA FY 2026 Tribal Justice Training and Technical Assistance Program aims to enhance Tribal justice systems through specialized technical support. This funding opportunity addresses critical issues such as violent crime and substance-use related crime, including opioids. By assisting federally recognized Indian Tribes, the program promotes the development of sustainable legal and corrections infrastructure while fostering collaboration with federal, state, and local partners. Applications are due by October 28, 2026, at 8:59 p.m. ET.

The OJJDP FY 2026 Community and Schools Youth Drug Prevention Program aims to combat youth substance use through comprehensive prevention strategies. This initiative invites applications from states, local governments, and nonprofit organizations to develop programs that educate and support youth in schools and community settings. By fostering collaboration with law enforcement and community coalitions, the program seeks to build capacity and implement effective interventions to protect the well-being of American youth.

The FY 2027 Department of War Multidisciplinary Research Program of the University Research Initiative (MURI) aims to fund U.S. academic teams conducting innovative research to tackle complex challenges for the Department of War. Established in 1985, MURI promotes collaboration among diverse scientific disciplines, enhancing the defense workforce and addressing critical areas of interest through multidisciplinary research efforts at U.S. universities.

The BJA FY 2026 National Center for Veterans Justice aims to enhance support for veterans in the criminal justice system. By providing specialized training and resources to law enforcement and service providers, the center will address critical gaps in veteran identification and coordination among agencies. This initiative seeks to improve outcomes for veterans experiencing issues like PTSD and military sexual trauma, ultimately strengthening public safety and ensuring effective responses to their unique needs.

The BJA FY 2026 Paul Coverdell Forensic Science Improvement- Competitive Grants Program aims to enhance forensic science and medical examiner/coroner services across the U.S. This funding opportunity supports state and local government laboratories in improving their capabilities to ensure justice and public safety. Applications are due by November 5, 2026, at 8:59 p.m. ET, promoting advancements in forensic practices to better serve law enforcement and communities.

The BJA FY26 Paul Coverdell Forensic Science Improvement - Formula Grants Program supports state agencies in enhancing forensic science capabilities. The program aims to improve public safety by funding initiatives that strengthen forensic science and support law enforcement efforts. Eligible applicants can submit their full applications through JustGrants by November 6, 2026. This funding is crucial for addressing ongoing challenges in the justice system, including violent crime and public safety concerns.

The OJJDP FY 2026 Multistate Mentoring Programs aims to provide crucial mentoring services to at-risk youth, helping them avoid delinquency and victimization. This funding opportunity emphasizes the importance of one-on-one, group, and peer mentoring approaches. The program aligns with the U.S. Department of Justice's commitment to public safety and juvenile justice reform, addressing the needs of vulnerable populations and fostering positive youth development.

The OJJDP FY 2026 Strengthening Internet Crimes Against Children (ICAC) program aims to enhance the technological investigative capacity of ICAC task forces nationwide. Through this funding opportunity, the program will support the development and refinement of investigative tools and methods to combat child sexual abuse material, exploitation, and trafficking. The deadline for application submission is November 5, 2026, at 8:59 p.m. ET, emphasizing the urgency of addressing these critical issues.

The FY 2027 Department of War Multidisciplinary Research Program (MURI) funds U.S. academic teams engaged in innovative basic research addressing future defense challenges. Established in 1985, MURI emphasizes collaboration across multiple scientific disciplines to tackle complex, DoW-relevant issues. By fostering partnerships among faculty, postdoctoral researchers, and students, the program aims to advance the U.S. defense industrial base and nurture a skilled scientific workforce, contributing to significant breakthroughs in military technology and economic growth.

The OJJDP FY 2026 Victims of Child Abuse Act Training and Technical Assistance program aims to enhance the skills of child abuse professionals. This initiative will promote coordinated investigations and improve intervention strategies for child abuse victims. By providing essential training on effective interviewing, investigative techniques, and interagency collaboration, the program seeks to elevate the quality of care and support available to affected children and families. Applications are due by November 5, 2026.

The BJA FY 2026 Rural Violent Crime Reduction Initiative aims to empower local law enforcement in rural areas to combat violent crime effectively. This funding opportunity provides resources for personnel, technology, and data analytics to enhance crime prevention strategies. Eligible applicants can utilize updated equipment and training to address specific violent crime challenges, ensuring safer communities through innovative approaches and strategic resource allocation. Applications are due by November 6, 2026.

The Fiscal Year 2027 Department of War Multidisciplinary Research Program aims to fund innovative research teams from U.S. universities. Established in 1985, this initiative addresses complex challenges faced by the Department of War, fostering collaboration across various scientific disciplines. By integrating world-class faculty and graduate students, the program seeks to cultivate a skilled workforce poised to enhance the U.S. defense capabilities and contribute to the advancement of the defense industrial base.

The BJA FY 2026 Students, Teachers, and Officers Preventing (STOP) School Violence Program aims to enhance school safety by funding initiatives that train staff and students, develop threat assessment teams, and implement technology solutions like anonymous reporting systems. This program supports effective strategies to identify and mitigate risks of school violence, ensuring students have the tools necessary to foster a secure learning environment while adhering to the guidelines set forth by the STOP School Violence Act.

The State Biomonitoring Cooperative Agreement aims to enhance public health laboratories' ability to conduct biomonitoring and assess human exposure to environmental chemicals. This funding opportunity emphasizes community investigations, state-level studies, and emerging chemicals not covered in the National Exposure Report. By improving laboratory capacity and fostering collaboration, the initiative seeks to identify harmful exposures and evaluate intervention effectiveness over a three-year period.

The National Institute of Neurological Disorders and Stroke (NINDS) is collaborating with other NIH institutes to enhance rigor and replicability in biomedical and behavioral research. This initiative aims to support projects focused on assessing the impact of improved research practices, developing frameworks for study selection, and measuring the generalizability of findings. Currently, applications are not being solicited, allowing researchers time to prepare collaborative proposals.

The John H. Prescott Marine Mammal Rescue Assistance Grant supports the recovery and care of sick or injured marine mammals through federal assistance to the U.S. National Marine Mammal Stranding and Entanglement Response Networks. Eligible applicants must provide a Prescott Letter of Eligibility, confirming their participation in the network. This program aims to enhance marine mammal health monitoring and response capabilities across the country, ensuring timely and effective interventions for stranded marine life.

The BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) Competitive Grants Program aims to enhance the capacity of state and local government crime laboratories for processing DNA samples. This program focuses on using DNA technology to improve forensic efficiency and implement Rapid DNA in booking stations. It targets jurisdictions with operational challenges, ensuring fair access to funding. Eligible agencies can apply for both competitive and formula CEBR funding.

The National Institute of Neurological Disorders and Stroke (NINDS) aims to enhance research on Amyotrophic Lateral Sclerosis (ALS) through intermediate patient population expanded access protocols. These protocols will provide investigational drugs to ALS patients while collecting vital data to inform future treatments and care strategies. This initiative seeks to better understand the disease's biomarkers, patient experiences, and the overall impact of investigational therapies, fostering advancements in ALS research and care.

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Hemophilia Health Equity Fund

Help with healthcare costs for hemophilia (health equity fund)

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Health Equity Funds offer help to eligible patients living in areas identified as having increased social and financial needs, as well as higher rates of chronic conditions. Eligibility is determined in part by home address zip code. 

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Mucopolysaccharidosis Type III (MPS III) Fund

Help with healthcare costs for mucopolysaccharidosis type III

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses. 

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Mucopolysaccharidosis Type VII (MPS VII) Fund

Help with healthcare costs for mucopolysaccharidosis type VII

This TotalAssist Health Equity Fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Mucopolysaccharidosis Type VII (MPS VII) Health Equity Fund

Help with healthcare costs for mucopolysaccharidosis type VII (health equity)

This TotalAssist Health Equity Fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Health Equity Funds offer help to eligible patients living in areas identified as having increased social and financial needs, as well as higher rates of chronic conditions. Eligibility is determined in part by home address zip code.

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant.